Gsk (GLAXF) Share-based Compensation (2011 - 2013)

Gsk (GLAXF) recorded quarterly Share-based Compensation of $3.2 million in Q4 2013, up 301.64% quarter-over-quarter from -$1.6 million in Q4 2012, and up 301.64% on a YoY basis from $806222.3 in Q4 2012.

Gsk (GLAXF) Share-based Compensation (2011 - 2013) Analysis & Trends

Gsk's Share-based Compensation history runs 3 years deep, the most recent figure standing at $3.2 million for Q4 2013.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 161.00 Mn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 300.00 Mn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 444.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 185.00 Mn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 75.00 Mn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 218.00 Mn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 272.00 Mn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 146.00 Mn
10 Gsk - - 7.76 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2013 3.24 Mn
Dec 31, 2013 3.24 Mn
Dec 31, 2012 -1.61 Mn
Dec 31, 2012 -1.61 Mn
Dec 31, 2011 4.71 Mn
Dec 31, 2011 4.71 Mn